& Kat, i'll add a re-thought..... I've said / a
Post# of 157773
(Total Views: 275)
Posted On: 10/08/2025 9:29:08 PM
& Kat, i'll add a re-thought.....
I've said / asked ---- how would an ICI mfgr benefit from directly investing into Cytodyn, with market dosing being physicians choice ??
Only thing I can / could see is --- once proven your ICI works with LL, the ICI would buy in advance a supply of LL.
& if, if our mTNBC PD-L1 protocol does go multiple ICI's, that justifies the above thought....
Including Cytodyn watches the ICI industry foot the bulk billing on expanding their already sales & marketing to now include the LL combos for us.
If Cytodyn does go multiple subtype tumors & simply re-doses the same patients, those thoughts look like a seriously real potential.
( not to mention already having our patient pool )
ICI mfgr's push combo awareness --- Cytodyn stays lean, mean profit machine.
& again, no need for a GSK level of 60k+ employees & etc.
Of course including your past comments of Cytodyn still needing legal expansion & other certain departments.
But would be an all around outstanding position for Cytodyn
I've said / asked ---- how would an ICI mfgr benefit from directly investing into Cytodyn, with market dosing being physicians choice ??
Only thing I can / could see is --- once proven your ICI works with LL, the ICI would buy in advance a supply of LL.
& if, if our mTNBC PD-L1 protocol does go multiple ICI's, that justifies the above thought....
Including Cytodyn watches the ICI industry foot the bulk billing on expanding their already sales & marketing to now include the LL combos for us.
If Cytodyn does go multiple subtype tumors & simply re-doses the same patients, those thoughts look like a seriously real potential.
( not to mention already having our patient pool )
ICI mfgr's push combo awareness --- Cytodyn stays lean, mean profit machine.
& again, no need for a GSK level of 60k+ employees & etc.
Of course including your past comments of Cytodyn still needing legal expansion & other certain departments.
But would be an all around outstanding position for Cytodyn
(2)
(0)